title: Induction of soft tissue tumours in F344 rats by subcutaneous, intramuscular, intra-articular, and retroperitoneal injection of nickel sulphide (Ni3S2).
abstract: The carcinogenicity of nickel sulphide (Ni3S2) injected into subcutaneous (s.c.), intramuscular (i.m.), or retroperitoneal intrafat (i.f.) tissue, or the intra-articular space (i.a.) of male F344 rats was studied. Rats were given a single injection of 0.5 mg of Ni3S2 and were observed for 48 weeks. Malignant soft tissue tumours were induced in 18/19 rats (95 per cent) by s.c. injection, 19/20 rats (95 per cent) by i.m. injection, in 16/19 rats (84 per cent) by i.a. injection, and in 9/20 rats (45 per cent) by i.f. injection of Ni3S2. The i.f. injection of Ni3S2 resulted in a lower tumour incidence and the appearance of tumours 10 weeks later than its injection by other routes. The tumours were examined histologically, ultrastructurally, and immunohistochemically with antibodies against desmin, vimentin, and cytokeratin. The 62 tumours induced by injection of Ni3S2 by different routes were identified as rhabdomyosarcomas (RMS, 35), malignant fibrous histiocytomas (MFH, 18), fibrosarcomas (FS, 5), and unclassified sarcomas (4). All 19 tumours induced by i.m. injection of Ni3S2 were rhabdomyosarcomas; those induced by s.c. or i.f. injection were mainly MFHs. However, a number of RMSs were also found in groups that received i.a., s.c., and i.f. injections; five FSs also developed in these groups. Four sarcomas induced by s.c. and i.a. injections were not classified. No synovial sarcoma developed.
authors.affiliation: Second Department of Pathology, School of Medicine, University of Tokushima, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Shibata
authors.forename: K
authors.initials: K
authors.lastname: Izumi
authors.forename: N
authors.initials: N
authors.lastname: Sano
authors.forename: A
authors.initials: A
authors.lastname: Akagi
authors.forename: H
authors.initials: H
authors.lastname: Otsuka
mesh_terms: D000818:Animals; D005354:Fibrosarcoma / Q000473:pathology; D018219:Histiocytoma, Benign Fibrous / Q000473:pathology; D007270:Injections, Intra-Articular; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008297:Male; D009532:Nickel / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D011916:Rats, Inbred F344; D012187:Retroperitoneal Space; D012208:Rhabdomyosarcoma / Q000473:pathology; D012513:Sarcoma, Experimental / Q000139:chemically induced / Q000473:pathology*; D012983:Soft Tissue Neoplasms / Q000139:chemically induced / Q000473:pathology*
chemical_list: D009532:Nickel; C017558:nickel sulfide